Join the Endometrial Cancer group to help and get support from people like you.
Endometrial Cancer News
Related terms: Cancer, Endometrial, Cancer, Uterine, Endometrial Adenocarcinoma, Endometrial Carcinoma, Uterine Adenocarcinoma, Uterine Cancer, Uterine corpus cancer
Ultrasound May Be Unreliable in Spotting Endometrial Cancer in Black Women
TUESDAY, July 2, 2024 – Ultrasound cannot reliably rule out endometrial cancer in Black women given how readings are now assessed, a new study argues. Transvaginal ultrasound is commonly used to...
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
FRIDAY, June 21, 2024 – The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Breast Cancer Survivors Face Higher Odds for Second Cancer
THURSDAY, April 25, 2024 – People lucky enough to survive a breast cancer may still face heightened risks for other cancers later, a new study shows. The researchers stressed that the absolute risk...
Today's Young Adults Are Aging Faster, and That Might Help Spur Cancers
MONDAY, April 8, 2024 – Younger generations are aging more rapidly, and this could be leading to an increased risk of cancer, a new study says. People born in or after 1965 are 17% more likely to be...
Rucaparib Could Extend Survival for Uterine Cancer Patients
FRIDAY, March 22, 2024 – An already approved cancer drug could be an effective treatment for women with advanced, recurring uterine cancer, a new clinical trial shows. Rucaparib, which belongs to a...
High-Tech Screening Might Spot More Cancer Patients Who'd Benefit From Immunotherapy
FRIDAY, Dec. 29, 2023 – More patients could benefit from immunotherapy, a highly effective treatment for some cancers, new research suggests. Revising current testing guidelines so that a more...
White Women Overrepresented in Gynecologic Cancer Trials
TUESDAY, Dec. 12, 2023 – White women are disproportionately represented in clinical trials for gynecologic cancers, according to a study published online Dec. 7 in JAMA Network Open. Wafa Khadraoui, ...
Moderate, Heavy Use of Chemical Hair Relaxer Linked to Uterine Cancer
THURSDAY, Nov. 2, 2023 – Among postmenopausal Black women, moderate and heavy use of chemical hair relaxers is associated with an increased risk for uterine cancer, according to a study published...
Use of Hair Relaxers Raises Women's Odds for Uterine Cancer
FRIDAY, Oct. 13, 2023 – Older Black women who use chemical hair relaxers may be more likely to develop uterine cancer, new research suggests. Specifically, postmenopausal Black women who reported...
Could Ativan Pose Harm to People Battling Pancreatic Cancer?
THURSDAY, Aug. 17, 2023 – Sometimes patients with pancreatic cancer are prescribed the benzodiazepine lorazepam (Ativan) for anxiety, but that may be harming their health. A new study found this...
Outdoor Pollution Exposure Tied to Nonlung Cancers
THURSDAY, Aug. 10, 2023 – Outdoor air pollution is tied to a higher risk for nonlung cancers in older adults, according to a study published online Aug. 1 in Environmental Epidemiology. Yaguang Wei,...
Jemperli (dostarlimab-gxly) Plus Chemotherapy Approved in the US for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...
Selinexor Increases PFS for Endometrial Cancer With TP53 Mutations
FRIDAY, July 28, 2023 – Maintenance therapy with selinexor provides durable survival benefits for endometrial cancer with TP53 mutations, according to a study presented during the July 2023 session...
US FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4% 85.9% of patients had duration...
Ask a question
To post your own question to this support group, sign in or create an account.